Cosmo Pharmaceuticals Statistics

Total Valuation

FRA:C43 has a market cap or net worth of EUR 1.56 billion. The enterprise value is 1.44 billion.

Market Cap	1.56B
Enterprise Value	1.44B

Important Dates

The next estimated earnings date is Friday, March 6, 2026.

Earnings Date	Mar 6, 2026
Ex-Dividend Date	Jun 4, 2025

Share Statistics

Current Share Class	15.94M
Shares Outstanding	n/a
Shares Change (YoY)	+1.65%
Shares Change (QoQ)	-4.28%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	16.66%
Float	8.44M

Valuation Ratios

The trailing PE ratio is 25.92 and the forward PE ratio is 333.50.

PE Ratio	25.92
Forward PE	333.50
PS Ratio	8.53
PB Ratio	3.33
P/TBV Ratio	14.52
P/FCF Ratio	22.95
P/OCF Ratio	21.16
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.78, with an EV/FCF ratio of 21.23.

EV / Earnings	23.98
EV / Sales	7.91
EV / EBITDA	17.78
EV / EBIT	20.99
EV / FCF	21.23

Financial Position

The company has a current ratio of 3.84, with a Debt / Equity ratio of 0.01.

Current Ratio	3.84
Quick Ratio	3.59
Debt / Equity	0.01
Debt / EBITDA	0.03
Debt / FCF	0.04
Interest Coverage	763.58

Financial Efficiency

Return on equity (ROE) is 12.34% and return on invested capital (ROIC) is 8.80%.

Return on Equity (ROE)	12.34%
Return on Assets (ROA)	6.88%
Return on Invested Capital (ROIC)	8.80%
Return on Capital Employed (ROCE)	12.24%
Revenue Per Employee	549,009
Profits Per Employee	180,696
Employee Count	322
Asset Turnover	0.29
Inventory Turnover	3.64

Taxes

In the past 12 months, FRA:C43 has paid 12.17 million in taxes.

Income Tax	12.17M
Effective Tax Rate	16.87%

Stock Price Statistics

The stock price has increased by +48.12% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+48.12%
50-Day Moving Average	72.27
200-Day Moving Average	63.83
Relative Strength Index (RSI)	81.39
Average Volume (20 Days)	160

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:C43 had revenue of EUR 182.27 million and earned 59.99 million in profits. Earnings per share was 3.67.

Revenue	182.27M
Gross Profit	134.49M
Operating Income	68.72M
Pretax Income	72.15M
Net Income	59.99M
EBITDA	80.45M
EBIT	68.72M
Earnings Per Share (EPS)	3.67

Full Income Statement

Balance Sheet

The company has 126.63 million in cash and 2.70 million in debt, giving a net cash position of 123.93 million.

Cash & Cash Equivalents	126.63M
Total Debt	2.70M
Net Cash	123.93M
Net Cash Per Share	n/a
Equity (Book Value)	466.98M
Book Value Per Share	28.88
Working Capital	138.51M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 73.50 million and capital expenditures -5.75 million, giving a free cash flow of 67.76 million.

Operating Cash Flow	73.50M
Capital Expenditures	-5.75M
Free Cash Flow	67.76M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 73.79%, with operating and profit margins of 37.70% and 32.91%.

Gross Margin	73.79%
Operating Margin	37.70%
Pretax Margin	39.59%
Profit Margin	32.91%
EBITDA Margin	44.14%
EBIT Margin	37.70%
FCF Margin	37.17%

Dividends & Yields

This stock pays an annual dividend of 2.05, which amounts to a dividend yield of 2.95%.

Dividend Per Share	2.05
Dividend Yield	2.95%
Dividend Growth (YoY)	2.50%
Years of Dividend Growth	2
Payout Ratio	94.36%
Buyback Yield	-1.65%
Shareholder Yield	1.30%
Earnings Yield	3.86%
FCF Yield	4.36%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:C43 has an Altman Z-Score of 6.36 and a Piotroski F-Score of 4.

Altman Z-Score	6.36
Piotroski F-Score	4